Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2016 1
2017 1
2019 1
2020 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
METHODS: This is an open label, multicenter, single arm, phase II study designed to assess activity, safety and efficacy of cabozantinib in mRCC patients progressed after an adjuvant or first line anti-Programmed Death (PD)-1/PD-Ligand (PD-L) 1-based therapy. Primary endpo …
METHODS: This is an open label, multicenter, single arm, phase II study designed to assess activity, safety and efficacy of cabozantinib in …
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Di Costanzo F, Napolitano F, Salomone F, Amato AR, Alberico G, Migliaccio F, Pecoraro G, Marra A, Crocetto F, Ruffo A, Scagliarini S, Rossetti S, Puglia L, Di Napoli M, Bianco R, Servetto A, Formisano L. Di Costanzo F, et al. Cancers (Basel). 2023 Dec 4;15(23):5703. doi: 10.3390/cancers15235703. Cancers (Basel). 2023. PMID: 38067406 Free PMC article.
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
Vitale MG, Pipitone S, Venturelli M, Baldessari C, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L, Rossetti S, Caserta C, Bracarda S, Iacovelli R, Masini C, Cortellini A, Di Girolamo S, Buti S, Fornarini G, Carrozza F, Santoni M, Caputo F, Giaquinta S, Balduzzi S, D'Amico R, Vitale G, Mighali P, Sabbatini R. Vitale MG, et al. Clin Genitourin Cancer. 2020 Dec;18(6):477-488. doi: 10.1016/j.clgc.2020.05.010. Epub 2020 May 20. Clin Genitourin Cancer. 2020. PMID: 32732112
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale MG, Ciccarese C, Di Lorenzo G, Palesandro E, Conteduca V, Basso U, Naglieri E, Farnesi A, Aieta M, Borsellino N, La Torre L, Iovane G, Bonomi L, Gasparro D, Ricevuto E, De Tursi M, De Vivo R, Lo Re G, Grillone F, Marchetti P, De Vita F, Scavelli C, Sini C, Pisconti S, Crispo A, Gebbia V, Maestri A, Galli L, De Giorgi U, Iacovelli R, Buonerba C, Cartenì G, D'Aniello C. Facchini G, et al. J Transl Med. 2019 Aug 29;17(1):296. doi: 10.1186/s12967-019-2047-4. J Transl Med. 2019. PMID: 31464635 Free PMC article.
Identification of an ascorbate-dependent cytochrome b of the tonoplast membrane sharing biochemical features with members of the cytochrome b561 family.
Preger V, Scagliarini S, Pupillo P, Trost P. Preger V, et al. Planta. 2005 Jan;220(3):365-75. doi: 10.1007/s00425-004-1360-0. Epub 2004 Sep 9. Planta. 2005. PMID: 15365836
Two membrane-bound, ascorbate-dependent b-type cytochromes were identified in etiolated bean (Phaseolus vulgaris L.) hypocotyls. Following solubilization of microsomal membranes and anion-exchange chromatography at pH 8.0, two major cytochrome peaks (P-I and P-II) were sep …
Two membrane-bound, ascorbate-dependent b-type cytochromes were identified in etiolated bean (Phaseolus vulgaris L.) hypocotyls. Foll …
Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS).
Mercadante S, Marchetti P, Cuomo A, Caraceni A, Mediati RD, Mammucari M, Natoli S, Lazzari M, Dauri M, Airoldi M, Azzarello G, Bandera M, Blasi L, Cartenì G, Chiurazzi B, Costanzo BVP, Degiovanni D, Fusco F, Guardamagna V, Iaffaioli V, Liguori S, Lorusso V, Mameli S, Mattioli R, Mazzei T, Melotti RM, Menardo V, Miotti D, Moroso S, De Santis S, Orsetti R, Papa A, Ricci S, Sabato AF, Scelzi E, Sofia M, Tonini G, Aielli F, Valle A; IOPS MS study group. Mercadante S, et al. Adv Ther. 2017 Jan;34(1):120-135. doi: 10.1007/s12325-016-0440-4. Epub 2016 Nov 21. Adv Ther. 2017. PMID: 27873235 Free PMC article.